IP Library › Granted Patent US 8,765,762
Granted Patent B2
US 8,765,762 · App. 13/791,675 · Granted Jul 1, 2014

Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome

Inventors: Roland Werner Bürli (Bishop's Stortford, GB); William Rameshchandra Krishna Esmieu (Cambridge, GB); Christopher James Lock (Burwell, GB); Karine Fabienne Malagu (Saffron Walden, GB); Andrew Pate Owens (Huntingdon, GB); William E. Harte (Moorpark, CA)
Assignee: Usher III, Initiative, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,765,762
App. No.
13/791,675
Granted
Jul 1, 2014
Kind
B2
Abstract

Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration and Usher Syndrome, and hearing loss associated with Usher Syndrome are described herein.

Claims (20)

1. A compound having the structure:

or a pharmaceutically acceptable salt thereof.

2. A composition comprising an effective amount of a compound or pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or vehicle.

3. A method for treating a retinal degenerative disease, comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt of the compound of claim 1 .

4. The method of claim 3 , wherein the retinal degenerative disease is retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration, or Usher Syndrome.

5. The method of claim 4 , wherein the Usher Syndrome is Usher I, Usher II or Usher III Syndrome.

6. The method of claim 3 , wherein the retinal degenerative disease is Usher III Syndrome.

7. A method for treating hearing loss associated with Usher syndrome, comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt of the compound of claim 1 .

8. The method of claim 7 , wherein the Usher Syndrome is Usher I, Usher II or Usher III Syndrome.

9. The method of claim 7 , wherein the Usher Syndrome is Usher III Syndrome.

10. A compound having the structure:

or a pharmaceutically acceptable salt thereof.

11. A composition comprising an effective amount of a compound or pharmaceutically acceptable salt of the compound of claim 10 and a pharmaceutically acceptable carrier or vehicle.

12. A method for treating a retinal degenerative disease, comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt of the compound of claim 10 .

13. The method of claim 12 , wherein the retinal degenerative disease is retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration, or Usher Syndrome.

14. The method of claim 13 , wherein the Usher Syndrome is Usher I, Usher II or Usher III Syndrome.

15. The method of claim 12 , wherein the retinal degenerative disease is Usher III Syndrome.

16. A method for treating hearing loss associated with Usher syndrome, comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt of the compound of claim 10 .

17. The method of claim 16 , wherein the Usher Syndrome is Usher I, Usher II or Usher III Syndrome.

18. The method of claim 16 , wherein the Usher Syndrome is Usher III Syndrome.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2013
From: HARTE, WILLIAM E.
To: USHER III INITIATIVE, INC.
Reel/Frame 031324/0473 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2013
From: BIOFOCUS DPI LTD.
To: USHER III INITIATIVE, INC.
Reel/Frame 030953/0476 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SECOND ASSIGNEE'S NAME TO "WILLIAM RAMESHCHANDRA KRISHNA ESMIEU" PREVIOUSLY RECORDED ON REEL 030279 FRAME 0626. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT NAME OF THE SECOND ASSIGNEE IS "WILLIAM RAMESHCHANDRA KRISHNA ESMIEU". Recorded Jul 8, 2013
From: BURLI, ROLAND WERNER; ESMIEU, WILLIAM RAMESHCHANDRA KRISHNA; LOCK, CHRISTOPHER JAMES; MALAGU, KARINE FABIENNE; OWENS, ANDREW PATE
To: BIOFOCUS DPI LTD.
Reel/Frame 030763/0860 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2013
From: BURLI, ROLAND WERNER; ESMIEU, WILLIAM RAMESHCCHANDRA KRISHNA; LOCK, CHRISTOPHER JAMES; MALAGU, KARINE FABIENNE; OWENS, ANDREW PATE
To: BIOFOCUS DPI LTD.
Reel/Frame 030729/0626 →
Continuity (2)
Provisional Application 61718593 · Oct 25, 2012
Related Publication 20140121205A1 · May 1, 2014